R Eric Davis
#172,614
Most Influential Person Now
Researcher
R Eric Davis's AcademicInfluence.com Rankings
R Eric Daviscomputer-science Degrees
Computer Science
#10613
World Rank
#11156
Historical Rank
Computational Linguistics
#2670
World Rank
#2699
Historical Rank
Machine Learning
#4840
World Rank
#4897
Historical Rank
Artificial Intelligence
#5211
World Rank
#5282
Historical Rank
Download Badge
Computer Science
R Eric Davis's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is R Eric Davis Influential?
(Suggest an Edit or Addition)R Eric Davis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (2000) (9767)
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma (2010) (1436)
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia (2001) (1215)
- Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells (2001) (1101)
- Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. (2007) (976)
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways (2008) (971)
- ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. (2003) (882)
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma (2008) (828)
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. (2016) (685)
- A loss-of-function RNA interference screen for molecular targets in cancer (2006) (635)
- In vivo detection and imaging of phosphatidylserine expression during programmed cell death. (1998) (546)
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. (2014) (500)
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion (2013) (401)
- Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol (2001) (391)
- Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. (2008) (361)
- Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. (1997) (346)
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. (2018) (337)
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience (2014) (332)
- Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling (2005) (304)
- Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* (2005) (297)
- Cooperative epigenetic modulation by cancer amplicon genes. (2010) (273)
- The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. (1999) (272)
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma (2012) (256)
- Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. (2014) (232)
- Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. (2014) (221)
- The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress (2007) (221)
- A library of gene expression signatures to illuminate normal and pathological lymphoid biology (2006) (216)
- Cybrids in Alzheimer's disease: A cellular model of the disease? (1997) (216)
- Imaging of apoptosis (programmed cell death) with 99mTc annexin V. (1999) (208)
- Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. (2005) (192)
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia. (2012) (187)
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. (2012) (172)
- Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. (2019) (153)
- Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. (2004) (150)
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies (2016) (132)
- Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. (2012) (127)
- Casein kinase 1α governs antigen-receptor-induced NF-κB activation and human lymphoma cell survival (2009) (124)
- Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide (2010) (118)
- PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma (2013) (116)
- Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes (2016) (115)
- Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar) (1999) (111)
- Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. (2015) (97)
- Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. (2016) (93)
- AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. (2017) (89)
- Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen (2008) (83)
- HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes (2017) (82)
- Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. (2016) (81)
- Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment (2013) (80)
- Molecular diagnosis of lymphoid malignancies by gene expression profiling. (2002) (78)
- The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. (2012) (77)
- Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. (2013) (77)
- MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. (2005) (77)
- Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. (2017) (74)
- A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. (2011) (72)
- The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma (2017) (72)
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma (2011) (69)
- Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy (2012) (66)
- Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. (1998) (66)
- Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models (2015) (61)
- Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas (2018) (59)
- FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (58)
- Management strategies and outcomes for very elderly patients with diffuse large B‐cell lymphoma (2016) (58)
- Protein Targeting Chimeric Molecules Specific for Bromodomain and Extra-terminal Motif Family Proteins are Active Against Pre-Clinical Models of Multiple Myeloma (2018) (57)
- The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression (2018) (56)
- Targeting B-cell receptor signaling: changing the paradigm. (2013) (55)
- Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. (2017) (55)
- Inhibitors of the NF-kappaB activation pathway from Cryptocarya rugulosa. (2009) (55)
- Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). (1999) (55)
- Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin (2009) (54)
- Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma. (2018) (54)
- Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease (2019) (53)
- Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer (2020) (52)
- The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway (2002) (51)
- MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). (1999) (51)
- The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy (2017) (50)
- CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma (2015) (50)
- Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma (2016) (50)
- PML mediates IFN-α-induced apoptosis in myeloma by regulating TRAIL induction (2005) (48)
- Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs (2017) (46)
- Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis. (2019) (46)
- Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). (1999) (46)
- Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen (2013) (45)
- Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study. (2017) (44)
- Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling (2010) (44)
- p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression (2014) (44)
- RNA Polymerase I Inhibition with CX‐5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma (2017) (44)
- A novel mitochondrial DNA-like sequence in the human nuclear genome. (1999) (43)
- Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. (2015) (42)
- Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. (2019) (41)
- CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel (2021) (38)
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma (2019) (38)
- PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. (2005) (38)
- BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. (2019) (36)
- Rapid activation of heat shock factor-1 DNA binding by H2O2 and modulation by glutathione in human neuroblastoma and Alzheimer's disease cybrid cells. (1999) (34)
- Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial (2019) (34)
- Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. (2016) (33)
- Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. (2018) (32)
- B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia (2017) (32)
- Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma. (2021) (32)
- Selective targeting of Toll‐like receptors and OX40 inhibit regulatory T–cell function in follicular lymphoma (2014) (31)
- CXCR5+CD8+ T cells are a distinct functional subset with antitumor activity (2019) (29)
- The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer (2013) (29)
- Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B‐cell acute lymphoblastic leukaemia (2016) (29)
- Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma (2017) (28)
- Guidelines for Cord Blood Unit Selection. (2020) (28)
- Small Molecule Inhibitors of IKB Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling (2005) (28)
- Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype (2020) (28)
- Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185 (2015) (26)
- Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. (2017) (26)
- A Cell-Based Assay for IκBα Stabilization Using A Two-Color Dual Luciferase-Based Sensor (2007) (25)
- Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (2022) (24)
- The risk of central nervous system relapses in patients with peripheral T-cell lymphoma (2018) (24)
- Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. (2016) (23)
- Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma (2019) (23)
- High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study (2017) (21)
- C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis (2017) (20)
- Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. (2005) (19)
- The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma (2017) (18)
- Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results (2019) (18)
- Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma (2017) (18)
- A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas (2014) (17)
- The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma (2020) (16)
- Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL) (2019) (16)
- Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma (2019) (15)
- Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activation. (2008) (15)
- Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma (2017) (13)
- HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN‐LABEL, PHASE II STUDY (2017) (12)
- The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. (2002) (12)
- Evaluation of Cord Blood Total Nucleated and CD34+ Cell Content, Cell Dose and 8-allele HLA-Match by Patient Ancestry. (2019) (12)
- Requirement for Ssbp2 in Hematopoietic Stem Cell Maintenance and Stress Response (2014) (11)
- Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 (2018) (10)
- BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? (2007) (10)
- Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML (2021) (10)
- Streptavidin-biotin immunotoxins: a new approach to purging bone marrow. (1991) (10)
- High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience (2016) (10)
- XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. (2013) (10)
- Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma (2016) (10)
- Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation. (2017) (10)
- Double Hit Lymphoma: M.D. Anderson Experience (2013) (9)
- The kinase inhibitor sorafenib induces cell death through a process involving induction of ER stress (2007) (9)
- Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma (2022) (9)
- ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition (2014) (8)
- Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML (2021) (8)
- B-Cell Maturation Antigen (BCMA)-Specific, CentyrinTM-Based, PiggyBacTM-Transposed CAR-T Memory Stem Cells Are Effective Against p53-/- and Patient-Derived Multiple Myeloma Tumors (2017) (8)
- Erratum: The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma (Blood Cancer Journal (2011) 1 (e46) DOI:10.1038/bcj.2011.46) (2014) (7)
- Pathognomonic and epistatic genetic alterations in B-cell non-Hodgkin lymphoma [preprint] (2020) (7)
- BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects (2016) (7)
- Frontline antibiotic therapy for early‐stage Helicobacter pylori‐negative gastric MALT lymphoma (2019) (7)
- SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy (2014) (6)
- OUTCOME OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER SECOND SALVAGE THERAPY: MD ANDERSON EXPERIENCE (2015) (6)
- Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (2019) (6)
- IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma (2021) (6)
- Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma (2017) (6)
- Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (6)
- Differential T‐cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals (2016) (6)
- Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia (2015) (6)
- A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor. (2007) (6)
- Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. (2012) (5)
- Detecting Förster resonance energy transfer in living cells by conventional and spectral flow cytometry (2021) (5)
- Technique for human bone marrow harvest. (1982) (5)
- Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL (2022) (5)
- Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition (2018) (5)
- Smart start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma. (2019) (5)
- Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. (2017) (5)
- Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML (2016) (5)
- Radiation and marrow infusion in leukaemia. Observations on a patient with chronic granulocytic leukaemia treated with whole-body radiation and infusion of isogenic marrow. (1967) (4)
- Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma (2022) (4)
- Racial disparities in access to alternative donor allografts persist in the era of “donors for all” (2021) (4)
- Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study (2018) (4)
- Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML. (2021) (4)
- Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma (2021) (4)
- Abstract PR01: Targeting multiple myeloma with universal SLAMF7-specific CAR T-cells (2018) (4)
- Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL (2020) (4)
- Non-Stereotypic Follicular Lymphoma B-Cell Receptors Recognize Vimentin as a Shared Autoantigen (2010) (4)
- The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma (2015) (4)
- Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy (2014) (4)
- The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat, (2011) (4)
- The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma (2011) (3)
- Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia (2017) (3)
- Connective Tissue Growth Factor (CTGF) Is Essential for Self Renewal and Proliferation of Mesenchymal Stromal Cells (MSCs) and Affects Leukemia-Stromal Interactions. (2010) (3)
- Basic References (3)
- The Risk of Central Nervous System (CNS) Relapses in Patients with Peripheral T-Cell Lymphoma (2016) (3)
- Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo (2013) (3)
- The Small Molecule JAK1/JAK2 Inhibitor INCB16562 Shows Single Agent Activity and Strongly Synergizes with Bcl-2 Inhibitors in Lymphoma (2011) (3)
- Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors (2020) (3)
- The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept (2013) (3)
- B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade (2022) (3)
- Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma (2021) (3)
- An immunotoxin for immunologic manipulation of marrow ex vivo in autologous transplantation for common acute lymphoblastic leukemia. (1986) (3)
- CD200 Is a Stem Cell-Specific Immunosuppressive Target in AML (2018) (2)
- distinct gene expression profile with unmutated immunoglobulin genes , inferior clinical outcome , and ZAP-70 expression identifies a chronic lymphocytic leukemia subtype (2003) (2)
- Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia (2019) (2)
- Cooperative Signaling Through the STAT3 and NF-kB Pathways in Subtypes of Diffuse Large B Cell Lymphoma (2008) (2)
- A UNIQUE T‐CELL MONOCLONAL ANTIBODY WITH POTENTIAL USES IN AUTOLOGOUS BONE MARROW TRANSPLANTATION (1983) (2)
- AML Genotype-Specific and Non-Specific Regulation of Mesenchymal Stromal Cell Transcriptome in the Bone Marrow Microenvironment (2014) (2)
- Abstract 13: PRMT1 as a therapeutic target in diffuse large B-cell lymphoma (2017) (2)
- Discovery of Predictive Gene Signatures for Tumor Sensitivity to MDM2 Inhibition in Development of a Novel MDM2 Inhibitor DS-3032b (2016) (2)
- Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting (2015) (2)
- Small Molecule Inhibitors of I K B Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling (2005) (2)
- Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (2015) (2)
- Role of IL-4 in Inducing Immunosuppressive Tumor Microenvironment in Follicular Lymphoma (2011) (2)
- Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma. (2016) (2)
- RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma (2015) (2)
- Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia (2013) (2)
- Safety and Activity of Lenalidomide and Rituximab in Previously Untreated Marginal Zone Lymphoma: Subgroup Analysis and Long-Term Follow-up of an Open-Label Phase II Trial (2017) (2)
- ARV-825, a BRD4 Inhibitor, Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Myeloid Leukemia and Overcomes Stroma Mediated Resistance by Modulating Chemokine Receptor, Cell Adhesion and Metabolic Targets (2016) (2)
- Immunological Effects and Predictive Gene Signatures in Patients with Relapsed Follicular Lymphoma Treated with CT-011, a Humanized Anti-PD-1 Monoclonal Antibody (2012) (2)
- Smart Stop: A Phase II Study of Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Chemotherapy in Patients with Newly Diagnosed DLBCL (2021) (2)
- Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy. (2019) (2)
- The B-Cell Receptor Is Required for Optimal Viability, Growth, and Chemotherapy Resistance of Diffuse Large B-Cell Lymphoma Cell Lines of the Germinal Center B-Cell Subtype (2014) (2)
- ONC201 Overcomes Chemotherapy Resistance By Upregulation of Bim in Multiple Myeloma (2016) (2)
- Mucin 20 (MUC20) Modulates Proteasome Assembly Chaperones through the c-MET Pathway and Is a Biomarker of Proteasome Inhibitor Sensitivity in Myeloma (2014) (2)
- Prosurvival and Chemoprotective Effects of Tumor-Associated Macrophages Reversed By Anti-CSF-1R Monoclonal Antibody in B-Cell Lymphomas (2014) (1)
- Abstract 3547: B cell receptor signaling regulates cellular metabolism in Chronic Lymphocytic Leukemia (2017) (1)
- Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma (2017) (1)
- Abstract B105: HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes (2016) (1)
- Analysis of Disparities in Time to Allogeneic Transplantation in Adults with Acute Myelogenous Leukemia. (2022) (1)
- Lineage-negative, CD34-negative, CD45-negative (Lin-CD34-CD45-) leukemia cells from primary adult AML samples have distinct stem cell-like properties (2015) (1)
- R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis (2014) (1)
- GCS-100 Induces Apoptosis of Acute Myeloid Leukemia Cells By Disrupting Galectin-Mediated Survival Signaling (2014) (1)
- Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism (2019) (1)
- Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor (2020) (1)
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in the activated B-cell subtype of diffuse large B-cell lymphoma (2018) (1)
- ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies (2016) (1)
- Molecular Aspects of Tonic B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma Provide Biomarkers and Targets for Specific Inhibition (2016) (1)
- Abstract 5606: Fibrinogen-like protein 2 drives malignant tumor progression in glioma (2017) (1)
- Hyperthermia Potentiates the Activity of Immunotoxin Conjugates against Common Acute Lymphoblastic Leukaemia Cells in Vitro a (1987) (1)
- Adoptive T-Cell Therapy with TCL1-Specific TCR for B-Cell Lymphomas (2018) (1)
- Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma (2016) (1)
- Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas (2015) (1)
- Intratumoral and Peripheral Blood T Cells Recognize Mutated Neo-Antigens in Follicular Lymphoma (2014) (1)
- HSP110 and MYD88: blame the chaperone. (2018) (1)
- PD-1+ T Cell Subsets in Follicular Lymphoma Tumor Microenvironment and Their Implications for Prognosis and Therapy (2011) (1)
- Analysis of Disparities in Speed to BMT Referral & Allograft in 279 Adults with AML: Non-Europeans Have Delayed Referrals & Cord Blood Can Facilitate Prompt Transplantation Regardless of Ancestry (2022) (1)
- IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study. (2019) (1)
- Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma (2019) (1)
- Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Phase I Results (2016) (1)
- Ablation of Autophagy-Related E1 Ligase Atg7 Primes Acute Myelogenous Leukemia Cells to Apoptosis, Sensitizes to Chemotherapy and Overcomes Stroma Mediated Protection (2014) (1)
- miR-181a promotes multiple pro-tumorigenic functions through targeting TGFβR3. (2021) (1)
- Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML (2020) (1)
- Analysis of the CD34+ cell to total nucleated cell content ratio of 619 transplanted and back-up cord blood units (2020) (1)
- Inaccuracies in assignment of patient race and ethnicity: implications for unrelated donor searches and healthcare delivery. (2022) (1)
- CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. (2022) (1)
- LENALIDOMIDE AND OBINUTUZUMAB WITH CHOP FOR NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA: PHASE I/II RESULTS (2017) (1)
- Targeting Autophagy Kinase ULK1 Can Reverse Bcl2 Inhibitor (ABT-199) Induced Autophagy to Overcome Acquired Resistance in Acute Myeloid Leukemia (2018) (1)
- CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma. (2007) (1)
- Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia (2018) (1)
- Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience. (2014) (1)
- RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (2017) (1)
- A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL (2022) (1)
- ONC201 Induces p53-Independent Apoptosis and Abrogates Stem Cell Function in Hematological Malignancies By Induction of ATF4 through Integrated Stress Response (2015) (1)
- IN VIVO IMAGING OF APOPTOSIS DURING CARDIAC ALLOGRAFT REJECTION USING RADIOLABELED ANNEXIN V (1998) (1)
- Abstract PR08: Metabolic adaptations establish immunotherapy resistance in melanoma (2018) (1)
- Therapeutic strategies to retard neuronal cell death in neurodegenerative diseases. (2001) (1)
- The Role of Radiation Therapy in the Treatment of Primary Mediastinal B Cell Lymphoma Treated with Rituximab containing Regimens (2014) (0)
- Abstract 2177: Long-term storage in TRIzol has little effect on microarray-based gene expression profiling in primary myeloma or acute myeloid leukemia cells (2010) (0)
- Silencing TG2 in Acute Myeloid Leukemia. Possible Role of TG2 in Microenvironment-Mediated Chemoresistance (2016) (0)
- MCL‐1 Up‐Regulation through MAPK Activation Confers Acquired Resistance to BCL‐2 Inhibitor ABT‐199 in Pre‐Clinical AML Models: Abstract: AML‐012 (2017) (0)
- Abst Intro The soluti on th Chom the is preser for fr the sa proce Author Sample Cell (2010) (0)
- Recognize Vimentin as a Shared Autoantigen Nonstereotyped Lymphoma B Cell Receptors (2013) (0)
- Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity (2014) (0)
- CXCR4 Chemokine Receptor as a therapeutic target in B-Cell Acute Lymphoblastic Leukemia (B-ALL) (2015) (0)
- CX-5461, a Novel RNA Polymerase I Inhibitor, Is Active Against Wild-Type and Mutant p53 Myeloma Models (2013) (0)
- Outcomes of diffuse large b-cell lymphoma with MYC and/or BCL2 protein expression treated with intensive chemotherapy. (2016) (0)
- Pre-BCR Signaling Activity Predicts Sensitivity To Syk Kinase Inhibition In B Cell Acute Lymphoblastic Leukemia (B-ALL) (2013) (0)
- PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY (2019) (0)
- Abstract 4360: Inhibition of HSP90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes (2016) (0)
- Acute Myeloid Leukemia Cells Acquire Stem Cell Features in the Bone Marrow Microenvironment (2014) (0)
- C-Reactive Protein Promotes Bone Destruction in Human Myeloma By Stimulating Myeloma Cell Production of Osteolytic Cytokines Via the CD32/FcγRII-p38MAPK-Twist Axis (2017) (0)
- Graft-versus-Host Disease in Gut Organs (2007) (0)
- Targeting NOTCH1-MYC-CD44 Axis to Eliminate Leukemia Initiating Cells (LIC) in T-ALL (2019) (0)
- Pre-BCR expression predicts sensitivity to SYK inhibition in B-cell acute lymphoblastic leukemia (2016) (0)
- Upregulation of MCL-1 through MAPK Activation Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML (2017) (0)
- Analyzing Patient Characteristics Who Received (DA) EPOCH-R for High Risk Diffuse Large B-Cell Lymphoma: MD Anderson Cancer Center Experience (2016) (0)
- Abstract 4694: The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma (2012) (0)
- ’ s response to reviews Title : Gm 40600 suppressed SP 2 / 0 isograft tumor by reducing Blimp 1 and Xbp 1 proteins (2019) (0)
- Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) overcomes adaptive drug resistance in acute myelogenous leukemia. (2023) (0)
- The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL (2015) (0)
- Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (0)
- Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (2022) (0)
- Abstract 4002: Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398 (2016) (0)
- The Novel Human Double Minute (HDM)-2 Inhibitor DS-5272 Is Active Both Alone, and In Combination With Other Novel Agents, Against Multiple Myeloma (2013) (0)
- Expression Of Truncated Protein Tyrosine Phosphatase, Receptor Type, O (PTPROt) Influences Multiple Myeloma Sensitivity To Bortezomib Through Akt Signaling, and Is a Favorable Clinical Prognostic Factor (2013) (0)
- HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes (2017) (0)
- IL-15 deficient colon carcinomas have decreased cytolytic lymphocytes and skewed myeloid cell populations (2020) (0)
- Abstract 941: B cells are required to generate optimal antitumor immunity in response to PD-1 blockade treatment (2019) (0)
- Pronounced Anti-Leukemia Activity in Vivo of the Novel Peptidic CXCR4 Antagonist LY2510924 As a Single Agent and in Combination with Chemotherapy (2014) (0)
- Abstract 1391: Single cell analysis of Lin-CD34-CD45- cells from primary AML samples reveals leukemia clones with stem cell-like properties distinct from CD34+CD38-CD123+ LSC (2015) (0)
- NF-κB Activation in Mesenchymal Stromal Cells Mediates Leukemia Cell Chemoresistance (2012) (0)
- FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation (2019) (0)
- Abstract 4264: NFκB activation in mesenchymal stromal cells induced by leukemia-stroma interaction plays a central role in stroma-mediated chemo-resistance of leukemic cells (2012) (0)
- Phase II clinical trail of patients with relapsed follicular lymphoma treated with a humanized antiprogrammed death-1 monoclonal antibody combined with rituximabrreport in the 54th ASH annual meeting (2013) (0)
- P-226 A role for transcriptional adaptor SSBP2 in hematopoietic stem cell maintenance and stress response (2013) (0)
- Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease (2022) (0)
- Bone Marrow Microenvironment Induces Stem Cell-Like Phenotype In Acute Myeloid Leukemia (2013) (0)
- Unique Effects of p53 −/− Leukemic Cells On Mesenchymal Stromal Cell Gene Expression Profile in Vitro (2012) (0)
- Abstracts from Proceedings of the Society of Hematologic Oncology 2015 Annual Meeting (2015) (0)
- Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma. (2022) (0)
- engraftment mesenchymal stromal cells and facilitates leukemia bone marrow Connective tissue growth factor regulates adipocyte differentiation of (2013) (0)
- Unraveling The Molecular and Metabolic Basis For Glutamine Addiction In Leukemias (2013) (0)
- MicroenvironmentPromotes Immune Evasion in the Tumor Lymphoma Tumor Cells in Human Follicular Cross Talk between Follicular Th Cells and (2013) (0)
- MONOCLONAL ANTIBODY‐RICIN CONJUGATE CYTOTOXIC TO CELLS EXPRESSING THE COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN (CALLA) (1987) (0)
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma (2014) (0)
- Abstract B110: Topoisomerase I inhibitors enhance efficacy of immunotherapy through a p53 regulatory pathway (2016) (0)
- New drugs 346 POSITIVE CORRELATION BETWEEN CIRCULATING NK CELLS AND DISEASE RESPONSE IN MANTLE CELL LYMPHOMA (MCL) TREATED WITH LENALIDOMIDE: FIRST IN VIVO DATA SUPPORTING NK-MEDIATED CYTOTOXICITY AS A MECHANISM OF ACTION (2011) (0)
- Abstract LB-239: An rnai sensitization screen identifies compensatory IKKα activation during IKKβ inhibition (2008) (0)
- Abstract 4881: Targeting the CXCR4 chemokine receptor thwarts stromal cell mediated drug resistance in B-cell acute lymphoblastic leukemia (B-ALL) (2014) (0)
- Abstract 487: ITI-1020, a novel PDE type 1 inhibitor, reduces tumor growth in triple negative breast cancer (TNBC) mouse models (2023) (0)
- PI3K/Akt signaling pathway regulates c-Myc via NFkB and GSK3b in mouse iMyc-Em B lymphoma cells (2006) (0)
- Integrated Analysis Of Genomic and Gene Expression Profiles In Follicular Lymphoma Reveals Subsets and Driver Genes Of Potential Microenvironmental Importance (2013) (0)
- Abstract 5746: CRISPR9-mediated FGL2-KO in tumor cells impairs tumor progression in brain and triggers antitumor immune memory systematically via NF-κB dependent Batf3 expression in DCs (2018) (0)
- Despite Increasing Size of Unrelated Donor (URD) Registries and the Global Cord Blood (CB) Inventory Racial Disparities in Access to URD and CB Grafts Persist: A Prospective 10 Year Analysis of 1,112 Patients (2016) (0)
- Effector and Regulatory T Cell Subsets in Follicular Lymphoma Tumors: Implications for Pathogenesis and Prognosis. (2012) (0)
- The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies (2015) (0)
- First-in-class Anti-tumor Agent ONC201 Induces Apoptosis in Hematological Malignancies with Wild Type and Mutant p53 (2015) (0)
- Selinexor (KPT-330) Is Not Cross-Resistant with Chemotherapy and Demonstrates Strong Synergy with Targeted Therapy in DLBCL (2014) (0)
- Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL (2018) (0)
- Intravenous Immunoglobulin G (IVIg) Suppresses HSP70-1 and Has Potential Therapeutic Effects Against Multiple Myeloma and Lymphoma (2013) (0)
- B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma: Tonic Alone in the Germinal Center B-Cell Subtype, Plus Self Antigen-Induced in the Activated B-Cell Subtype (2015) (0)
- Abstract 1700: Metabolic adaptations confer immunotherapy resistance in melanoma (2018) (0)
- Outcomes of de novo CD5+ diffuse large b-cell lymphoma (DLBCL) in the rituximab (R) era. (2017) (0)
- Abstract 1066: Imipridone ONC201 efficacy in refractory multiple myeloma via Erk1/2 inhibition and pro-apoptotic Bim upregulation: single agent and combinatorial approaches (2017) (0)
- Using Haplogictm & Recipient Ancestry: The Likelihood of Identifying an 8/8 HLA-Matched Unrelated Donor Can be Accurately Predicted at the Time of the Preliminary Search Markedly Improving Search Efficiency & Speed to Allograft: An 830 Patient Analysis (2017) (0)
- Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With (1999) (0)
- Vive la résistance: stem cells in mantle cell lymphoma (2011) (0)
- Abstract LB-176: Identification of mutations in histone modification genes in Hodgkin lymphoma (2015) (0)
- Treatment of Poor Prognosis Acute Myelogenous Leukemia with PSC-833 and Mitoxantrone, Etoposide, Cytarabine (1998) (0)
- Evaluation of Cord Blood (CB) TNC & CD34+ Cell Content, Cell Dose & Donor-Recipient 8-Allele HLA-Match By Patient Ancestry: An Analysis of 544 Units in a Racially & Ethnically Diverse Patient Population (2019) (0)
- Mesenchymal Stromal Cells From AML Bone Marrow Are Abnormal by Gene Expression Profiling. (2010) (0)
- MEK inhibition is selectively toxic to the genetically defined poor prognosis subset of multiple myeloma overexpressing the c-maf oncogene (2008) (0)
- Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory Title Engagement of CD 81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin (2009) (0)
- Mitochondrial ClpP-Media ted Proteolysis Induces Selective Cancer Cell Lethality Highlights (2019) (0)
- Killing 2 birds with 1 stone in DLBCL. (2021) (0)
- Disparities in speed to BMT consult and allograft in 279 adults with AML. (2022) (0)
- mediates chemoresistance B κ Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF- (2014) (0)
- meeting held in San Diego, CA, December 1997. 833 (Valspodar) : Presented in part at the American Society of Hematology Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With (2013) (0)
- Abstract 1887: Bone marrow-derived stromal cells and hypoxia promote glutamine dependency in leukemias. (2013) (0)
- Accumulation of Intracellular L-Lactate and Irreversible Disruption of Mitochondrial Membrane Potential upon Dual Inhibition of Oxphos and Lactate Transporter MCT-1 Induce Synthetic Lethality in T-ALL Via Mitochondrial Exhaustion (2021) (0)
- Abstract B080: Disruption of ADAM17-dependent cellular crosstalk inhibits tumor progression of pancreatic ductal adenocarcinoma (2022) (0)
- Correlating Fc ε RI Signaling with Dynamics using Single Quantum Dot Imaging (2009) (0)
- blockade of MAF oncogene expression A mechanistic rationale for MEK inhibitor therapy in myeloma based on (2011) (0)
- Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma (2014) (0)
- BR VS RCHOP AS INITIAL TREATMENT FOR ADVANCED STAGE FOLLICULAR LYMPHOMA: A MATCHED-PAIR ANALYSIS: PF489 (2019) (0)
- B-Cell Receptor Signaling Modulates Cholesterol Biosynthesis in Diffuse Large B-Cell Lymphoma (2022) (0)
- Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipients. (2023) (0)
- induces a p 53-dependent gene expression response Fludarabine treatment of patients with chronic lymphocytic leukemia (2004) (0)
- The role of transcription factor Runx2 in tumor infiltrating T cells (2013) (0)
- Comparison of Search Prognosis Algorithms Demonstrates the Value of HapLogicTM-Based Assessment in Predicting the Likelihood of Identifying 8/8 HLA-Allele Matched Unrelated Donors (URD) & Receiving an 8/8 URD Transplant (2020) (0)
- Despite Increasing Size of Unrelated Donor (URD) Registries and the Global CB Inventory Racial Disparities in Access to URD and CB Grafts Persist: A Prospective 10 Year Analysis of 1,112 Patients (2017) (0)
- Analysis of 154 Cord Blood Unit (CBU) Reports Demonstrates High Variability in Potency Data and Highlights the Need for Standardization of CBU Quality Assessment (2019) (0)
- Phosphatidylinositol 3-kinase dependent Myc expression is required for growth, and survival in mouse iMycEm B-lymphoma cells (2005) (0)
- In vitro chemosensitivity testing in the genomic era. (2008) (0)
- gene expression profile unmutated immunoglobulin genes, inferior clinical outcome, and distinct ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with (2013) (0)
- Evaluation of Cord Blood (CB) Unit TNC & CD34+ Cell Content & Donor-Recipient High-Resolution 8 HLA-Allele Match By Patient Ancestry: An Evaluation of 513 CB Units in a Racially & Ethnically Diverse Population of Adults with Hematologic Malignancies (2018) (0)
- Immunoglobulin Heavy Chain (IgH) Knockout Inhibits Proliferation of Pre-BCR+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) Via a FOXO1 and MYC Dependent Mechanism (2014) (0)
- Analysis of gene expression in normal and malignant lymphocytes using the Lymphochip cDNA microarray (1999) (0)
- Inaccuracies in Assignment of Patient Race & Ethnicity Highlights the Necessity of Staff Training to Accurately Capture Ancestry: Implications for Alternative Donor Allografts & Cancer Care Delivery (2022) (0)
- An optimized search prognosis tool to predict 8/8 HLA-allele matched unrelated donor procurement. (2023) (0)
- Creation of a New Search Prognosis Tool That Can Accurately Predict the Likelihood of Procuring an 8/8 HLA-Allele Matched Unrelated Donor (URD) in Patients of Both European and Non-European Ancestry (2022) (0)
- Cho B-S, Zeng Z, Mu H, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015;126(2):222-232. (2015) (0)
- Building lymphochip-computational algorithms for selecting clones highly expressed in B cell cDNA libraries (1999) (0)
- Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma (2018) (0)
- Analysis of 372 Adult Allograft Recipients Reveals Associations between Non-European Ancestry, Low Socioeconomic Status, and Receipt of HLA-Disparate Grafts (2022) (0)
- The metabolic basis of resistance to Adoptive T Cell Therapy (ACT) in patients with solid tumors (2018) (0)
- Prospective Evaluation of Cord Blood (CB) and Haplo-Identical (Haplo) Donor Availability Reveals Compromised Donor Access for Both CB and Haplo Grafts in Minority Patients (2016) (0)
- Genomic Analysis of B-Cell Lymphomas (2013) (0)
- Abstract PR02: Melanoma evolves complete immunotherapy resistance through acquisition of a hypermetabolic phenotype (2020) (0)
- The Role of Radiation Therapy in the Treatment of Primary Mediastinal B Cell Lymphoma Treated with Rituximab containing Regimens (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With R Eric Davis?
R Eric Davis is affiliated with the following schools:
